Comparing Cooper Companies, Inc. (The) (COO) and TearLab Corporation (TEAR)
Cooper Companies, Inc. (The) (NYSE: COO) and TearLab Corporation (NASDAQ:TEAR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitabiliy, earnings, valuation, analyst recommendations, risk and institutional ownership.
Valuation and Earnings
This table compares Cooper Companies, Inc. (The) and TearLab Corporation’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Cooper Companies, Inc. (The)||$2.05 billion||5.97||$635.85 million||$6.67||37.57|
|TearLab Corporation||$27.95 million||0.58||-$9.93 million||($3.33)||-0.85|
Cooper Companies, Inc. (The) has higher revenue and earnings than TearLab Corporation. TearLab Corporation is trading at a lower price-to-earnings ratio than Cooper Companies, Inc. (The), indicating that it is currently the more affordable of the two stocks.
Cooper Companies, Inc. (The) pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. TearLab Corporation does not pay a dividend. Cooper Companies, Inc. (The) pays out 0.9% of its earnings in the form of a dividend.
This is a summary of current recommendations and price targets for Cooper Companies, Inc. (The) and TearLab Corporation, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cooper Companies, Inc. (The)||0||3||6||0||2.67|
Cooper Companies, Inc. (The) currently has a consensus target price of $238.00, suggesting a potential downside of 5.04%. TearLab Corporation has a consensus target price of $5.75, suggesting a potential upside of 103.18%. Given TearLab Corporation’s stronger consensus rating and higher probable upside, analysts clearly believe TearLab Corporation is more favorable than Cooper Companies, Inc. (The).
Volatility & Risk
Cooper Companies, Inc. (The) has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, TearLab Corporation has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500.
Insider and Institutional Ownership
98.1% of Cooper Companies, Inc. (The) shares are held by institutional investors. Comparatively, 29.8% of TearLab Corporation shares are held by institutional investors. 1.6% of Cooper Companies, Inc. (The) shares are held by company insiders. Comparatively, 11.6% of TearLab Corporation shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Cooper Companies, Inc. (The) and TearLab Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cooper Companies, Inc. (The)||16.02%||15.88%||9.62%|
Cooper Companies, Inc. (The) beats TearLab Corporation on 10 of the 15 factors compared between the two stocks.
Cooper Companies, Inc. (The) Company Profile
The Cooper Companies, Inc. is a global medical device company. The Company operates through two business units: CooperVision, Inc. and CooperSurgical, Inc. CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses. CooperVision services three primary regions: the Americas; Europe, the Middle East and Africa (EMEA), and Asia Pacific. CooperVision offers spherical, aspherical, toric, multifocal and toric multifocal lens products in various modalities. CooperVision’s products are primarily manufactured at its facilities located in the United Kingdom, Puerto Rico, Hungary, Costa Rica and New York. CooperSurgical offers an array of products and services focused on advancing the health of families through a portfolio of products and services focusing on women’s health, fertility and diagnostics.
TearLab Corporation Company Profile
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor’s office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.
Receive News & Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related companies with MarketBeat.com's FREE daily email newsletter.